ABPI response to national overprescribing review
The ABPI supports today’s report on overprescribing and looks forward to working with system partners to implement its recommendations.
Overprescribing harms patients, diverts NHS resources that could otherwise be used to make innovative treatments more widely available and also has damaging environmental consequences. Richard Torbett
In response Richard Torbett, Chief Executive, ABPI, said:
“Overprescribing harms patients, diverts NHS resources that could otherwise be used to make innovative treatments more widely available and also has damaging environmental consequences.
"The ABPI and our members have a long history of working to reduce polypharmacy, support practice-based pharmacists and help manage transitions of care between hospital and general practice, where problems in managing medicines often occur.
"We also provide guidance on appropriate prescribing and encourage the highest levels of transparency in the interaction between industry and healthcare professionals through the ABPI’s Disclosure UK platform."
For an accurate assessment of the most recently available NHS medicines bill as agreed by DHSC and the ABPI, please see here.
Last modified: 20 September 2023
Last reviewed: 20 September 2023